RADX on Nasdaq
Radiopharm Theranostics Ltd
Pharmaceutical preparations company, listed on Nasdaq (RADX). Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Marker Therapeutics, Inc., Camp4 Therapeutics Corp or Kala Pharmaceuticals (United States), or pick any stock.
- TickerRADX on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersC31
- Incorporated inAustralia2
- Business addressLevel 3, 62 Lygon Street, Carlton Vic, 30532
- Filer categoryNon-accelerated filer, Emerging growth company2
See how the biggest companies compare on our leaderboards
Report on Form 20-F. We have included our website address in this Annual Report on Form 20-F solely as an inactive textual reference.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue11¢$3.6M
- Research and development88¢$27.5M
- Interest0¢$65.3K
- Income tax0¢$103.3K
Out of $3.6M in revenue.4 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Revenue from contracts with customers | 2.8M AUD | 3.6M AUD | 299.2K AUD |
| Cost of sales | -$2.5M | -$3.6M | |
| Gross Profit | $263.4K | $39.3K | $299.2K |
| Other income | $10.7M | $10.3M | $1.3M |
| Other losses | -$868.2K | -$351.6K | -$1.2M |
| General and administrative expenses | -$16.2M | -$14.6M | -$13.0M |
| Research and development expenses | -$50.0M | -$27.5M | -$23.1M |
| Share-based payments expenses | -$2.4M | -$1.9M | -$2.6M |
| Gain/(loss) on movement in contingent consideration | $1.7M | -$4.1M | -$8.9M |
| Operating loss | -$56.8M | -$38.2M | -$47.2M |
| Finance expenses | -$112.4K | -$65.3K | -$642.9K |
| Loss before income tax | -$56.9M | -$38.2M | -$47.9M |
| Income tax expense | -$54.4K | -$103.3K | -$96.4K |
| Loss for the year | -$57.0M | -$38.3M | -$47.9M |
| Exchange differences on translation of foreign operations | $621.4K | $464.0K | $203.0K |
| Owners of Radiopharm Theranostics Limited | -$54.5M | -$36.2M | -$45.8M |
| Non-controlling interests | -$1.8M | -$1.6M | -$2.0M |
| Total comprehensive loss for the year | -$56.3M | -$37.9M | -$47.7M |
| Basic loss per share (in Dollars per share) | -$1.79 | -$1.76 | -$12.41 |
| Diluted loss per share (in Dollars per share) | -$1.79 | -$1.76 | -$12.41 |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $4.1M | $29.1M | $18.6M | $11.7M |
| Trade and other receivables | $17.4M | $10.4M | $987.4K | |
| Other current assets | $340.2K | $337.1K | ||
| Total current assets | $21.9M | $39.9M | ||
| Property, plant and equipment | $46.1K | $53.5K | ||
| Intangible assets | $38.2M | $46.6M | $49.1M | |
| Total non-current assets | $38.2M | $46.6M | ||
| Total assets | $60.1M | $86.5M | ||
| Trade and other payables | $10.5M | $9.3M | $10.9M | |
| Other financial liabilities | $6.9M | $3.4M | ||
| Employee benefit obligations | $697.9K | $450.1K | $399.8K | |
| Deferred revenue | $806.4K | $1.7M | ||
| Total current liabilities | $18.9M | $14.9M | ||
| Other financial liabilities | $18.9M | $28.7M | ||
| Total non-current liabilities | $18.9M | $28.7M | ||
| Total liabilities | $37.8M | $43.6M | ||
| Net assets | $22.3M | $42.9M | ||
| Share capital | $209.9M | $176.6M | ||
| Other equity | $849.5K | $849.5K | ||
| Other reserves | $14.4M | $13.1M | ||
| Accumulated losses | -$199.7M | -$145.7M | ||
| Non-controlling interests | -$2.4M | -$1.9M | ||
| Total equity | $22.3M | $42.9M | $27.4M | $45.6M |
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $4.1M | $29.1M | $18.6M | $11.7M |
| Trade and other receivables | $17.4M | $10.4M | $987.4K | |
| Other current assets | $340.2K | $337.1K | ||
| Total current assets | $21.9M | $39.9M | ||
| Property, plant and equipment | $46.1K | $53.5K | ||
| Intangible assets | $38.2M | $46.6M | $49.1M | |
| Total non-current assets | $38.2M | $46.6M | ||
| Total assets | $60.1M | $86.5M | ||
| Trade and other payables | $10.5M | $9.3M | $10.9M | |
| Other financial liabilities | $6.9M | $3.4M | ||
| Employee benefit obligations | $697.9K | $450.1K | $399.8K | |
| Deferred revenue | $806.4K | $1.7M | ||
| Total current liabilities | $18.9M | $14.9M | ||
| Other financial liabilities | $18.9M | $28.7M | ||
| Total non-current liabilities | $18.9M | $28.7M | ||
| Total liabilities | $37.8M | $43.6M | ||
| Net assets | $22.3M | $42.9M | ||
| Share capital | $209.9M | $176.6M | ||
| Other equity | $849.5K | $849.5K | ||
| Other reserves | $14.4M | $13.1M | ||
| Accumulated losses | -$199.7M | -$145.7M | ||
| Non-controlling interests | -$2.4M | -$1.9M | ||
| Total equity | $22.3M | $42.9M | $27.4M | $45.6M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Receipts from customers (inclusive of GST) | $536.4K | $5.4M | $260.5K |
| Payments to suppliers and employees (inclusive of GST) | -$58.4M | -$42.8M | -$28.1M |
| Interest received | $549.2K | $800.3K | $50.5K |
| Research and development tax incentive received | $4.5M | $4.9M | |
| Net cash payments from operating activities | -$52.8M | -$36.6M | -$23.0M |
| Receipts for sale of intellectual property | $3.0M | ||
| Payments for license fee liabilities | -$5.4M | -$1.2M | -$320.0K |
| Net cash (payments)/proceeds from investing activities | -$5.4M | $1.8M | -$320.0K |
| Proceeds from issues of shares | $35.4M | $54.0M | $29.6M |
| Share issue transaction costs | -$2.0M | -$4.7M | -$1.5M |
| Proceeds from borrowings | $7.4M | ||
| Transaction costs related to loans and borrowings | -$218.6K | -$117.0K | |
| Repayment of borrowings | -$1.9M | -$5.2M | |
| Settlement with Lind | -$1.7M | ||
| Net cash proceeds from financing activities | $33.4M | $45.4M | $30.2M |
| Net (Decrease)/Increase in cash and cash equivalents | -$24.8M | $10.6M | $6.9M |
| Effects of exchange rate changes on cash and cash equivalents | -$149.9K | -$14.9K | -$25.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Radiopharm Theranostics Ltd, and when. Pick a name to see everywhere that person has worked.
- Chief executive officerRiccardo Canevari Mar 31, 2026 to now6
- Chief financial officerAaron James Laurita Apr 30, 2026 to now7
Board members and other officers (6)
- Chief Medical OfficerDimitris Voliotis May 6, 2026 to now8
- Board memberBruce Michael Goodwin Mar 18, 2026 to now9
- Board memberHester Denise Larkin Mar 31, 2026 to now10
- Board memberRiccardo Canevari Mar 31, 2026 to now6
- Board memberIan Lawrence Turner Apr 1, 2026 to now11
- Board memberNoel Donnelly Apr 1, 2026 to now12
Timeline
- Mar 31, 2026New chief executive Riccardo Canevari becomes CEO6
Filings
157 filings to the SEC since October 2021: 3 annual reports, 8 insider forms, 10 large holders, 136 other. The latest 20:
- Oct 14, 2026SCHEDULE 13G EDGAR
- Oct 5, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Oct 1, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 30, 202620-F ANNUAL REPORT EDGAR
- Sep 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 23, 2026EFFECT EDGAR
- Sep 23, 2026424B3 PROSPECTUS EDGAR
- Sep 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 14, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 14, 2026F-3 REGISTRATION STATEMENT EDGAR
- Sep 11, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 4, 2026SCHEDULE 13G EDGAR
- Sep 4, 2026SCHEDULE 13D EDGAR
- Aug 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 27, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 26, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
The 157 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Regal Partners Funds Management Pty LtdSCHEDULE 13G, 1 filing Oct 14, 202613
- JPMorgan ChaseSCHEDULE 13G/A, 3 filings Feb 11, 2025 to Jan 16, 202614
- REGAL PARTNERS HOLDINGS PTY LTDSCHEDULE 13G, 4 filings Jan 29, 2025 to Jan 8, 202615
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Stonepine Capital Management, LLC | 51,000,000 | $670.5K | 0.5% | No change |
| Hsbc Holdings PLC | 62,188 | $253.7K | 0.0% | +816 |
| Regal Partners Ltd | 40,138 | $168.2K | 0.0% | No change |
| PNC Financial Services Group, Inc. | 20,000 | $83.8K | 0.0% | +4,000 |
| UBS Group AG | 1,507 | $6.3K | 0.0% | −1,493 |
| Integrated Wealth Concepts LLC | 1,310 | $5.5K | 0.0% | New |
| Rhumbline Advisers | 195 | $817 | 0.0% | +74 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9SEC EDGARBruce Michael Goodwin, Board member
- 10SEC EDGARHester Denise Larkin, Board member
- 11SEC EDGARIan Lawrence Turner, Board member
- 12SEC EDGARNoel Donnelly, Board member
- 13
- 14
- 15